One of the basic factors in the assessment whether the patient is eligible for treatment with certain type of anticancer therapy is the p53 status of the tumour – specifically, whether the tumour expresses p53 or not; if it does, whether the p53 is wild-type or a cancer-specific isoform. The gene discussed is TP53; the disease is cancer.